Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
dc.contributor.author | James, N | |
dc.contributor.author | Sydes, M | |
dc.contributor.author | Clarke, Noel W | |
dc.contributor.author | Mason, M | |
dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Spears, M | |
dc.contributor.author | Ritchie, A | |
dc.contributor.author | Parker, C | |
dc.contributor.author | Russell, J | |
dc.contributor.author | Attard, G | |
dc.contributor.author | de Bono, J | |
dc.contributor.author | Cross, W | |
dc.contributor.author | Jones, R | |
dc.contributor.author | Thalmann, G | |
dc.contributor.author | Amos, CL | |
dc.contributor.author | Matheson, D | |
dc.contributor.author | Millman, R | |
dc.contributor.author | Alzouebi, M | |
dc.contributor.author | Beesley, S | |
dc.contributor.author | Birtle, A | |
dc.contributor.author | Brock, S | |
dc.contributor.author | Cathomas, R | |
dc.contributor.author | Chakraborti, P | |
dc.contributor.author | Chowdhury, S | |
dc.contributor.author | Cook, A | |
dc.contributor.author | Elliott, T | |
dc.contributor.author | Gale, J | |
dc.contributor.author | Gibbs, S | |
dc.contributor.author | Graham, J | |
dc.contributor.author | Hetherington, J | |
dc.contributor.author | Hughes, R | |
dc.contributor.author | Laing, R | |
dc.contributor.author | McKinna, F | |
dc.contributor.author | McLaren, D | |
dc.contributor.author | O'Sullivan, J | |
dc.contributor.author | Parikh, O | |
dc.contributor.author | Peedell, C | |
dc.contributor.author | Protheroe, A | |
dc.contributor.author | Robinson, A | |
dc.contributor.author | Srihari, N | |
dc.contributor.author | Srinivasan, R | |
dc.contributor.author | Staffurth, J | |
dc.contributor.author | Sundar, S | |
dc.contributor.author | Tolan, S | |
dc.contributor.author | Tsang, D | |
dc.contributor.author | Wagstaff, J | |
dc.contributor.author | Parmar, M | |
dc.date.accessioned | 2016-01-22T13:56:43Z | en |
dc.date.available | 2016-01-22T13:56:43Z | en |
dc.date.issued | 2015-12-21 | en |
dc.identifier.citation | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 2015: Lancet | en |
dc.identifier.issn | 1474-547X | en |
dc.identifier.pmid | 26719232 | en |
dc.identifier.doi | 10.1016/S0140-6736(15)01037-5 | en |
dc.identifier.uri | http://hdl.handle.net/10541/594615 | en |
dc.description.abstract | Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. | |
dc.language | ENG | en |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Lancet (London, England) | en |
dc.title | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. | en |
dc.type | Article | en |
dc.contributor.department | Warwick Medical School, University of Warwick, Coventry, UK | en |
dc.identifier.journal | Lancet | en |
refterms.dateFOA | 2020-04-21T13:35:02Z | |
html.description.abstract | Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. |